(a)Yang, F.; Zhang, Y.; Liang, H. Interactive association of drugs binding to human serum albumin. Int. J. Mol. Sci., 2014, 15(3), 3580-3595.
[http://dx.doi.org/10.3390/ijms15033580] [PMID: 24583848]
(b)Yang, M.; Hoppmann, S.; Chen, L.; Cheng, Z. Human serum albumin conjugated biomolecules for cancer molecular imaging. Curr. Pharm. Des., 2012, 18(8), 1023-1031.
[http://dx.doi.org/10.2174/138161212799315830] [PMID: 22272822]

(a)Mahammed, A.; Gray, H.B.; Weaver, J.J.; Sorasaenee, K.; Gross, Z. Amphiphilic corroles bind tightly to human serum albumin. Bioconjug. Chem., 2004, 15(4), 738-746.
[http://dx.doi.org/10.1021/bc034179p] [PMID: 15264860]
(b)Ranjbar, S.; Shokoohinia, Y.; Ghobadi, S.; Bijari, N.; Gholamzadeh, S.; Moradi, N.; Ashrafi-Kooshk, M.R.; Aghaei, A.; Khodarahmi, R. Studies of the interaction between isoimperatorin and human serum albumin by multispectroscopic method: Identification of possible binding site of the compound using esterase activity of the protein. ScientificWorldJournal, 2013, 2013, 305081.
[http://dx.doi.org/10.1155/2013/305081] [PMID: 24319355]
(c)Simard, J.R.; Zunszain, P.A.; Ha, C.E.; Yang, J.S.; Bhagavan, N.V.; Petitpas, I.; Curry, S.; Hamilton, J.A. Locating high-affinity fatty acid-binding sites on albumin by x-ray crystallography and NMR spectroscopy. Proc. Natl. Acad. Sci. USA, 2005, 102(50), 17958-17963.
[http://dx.doi.org/10.1073/pnas.0506440102] [PMID: 16330771]

(a)Wang, S.; Liu, S.; Zhang, Y.; He, J.; Coy, D.; Sun, L. Human serum albumin (HSA) and its applications as a drug delivery vehicle. 2020, 14(2), 698.
[http://dx.doi.org/10.36648/1791-809X.14.2.698]
(b)Senapati, S.; Mahanta, A.K.; Kumar, S.; Maiti, P. Controlled drug delivery vehicles for cancer treatment and their performance. Signal Transduct. Target. Ther., 2018, 3(1), 7-7.
[http://dx.doi.org/10.1038/s41392-017-0004-3] [PMID: 29560283]

Bratty, M.A. Spectroscopic and molecular docking studies for characterizing binding mechanism and conformational changes of human serum albumin upon interaction with telmisartan. Saudi Pharm. J., 2020, 28(6), 729-736.
[http://dx.doi.org/10.1016/j.jsps.2020.04.015] [PMID: 32550805]

(a)Ghuman, J.; Zunszain, P.A.; Petitpas, I.; Bhattacharya, A.A.; Otagiri, M.; Curry, S. Structural basis of the drug-binding specificity of human serum albumin. J. Mol. Biol., 2005, 353(1), 38-52.
[http://dx.doi.org/10.1016/j.jmb.2005.07.075] [PMID: 16169013]
(b)Li, M.; McAuley, E.; Zhang, Y.; Kong, L.; Yang, F.; Zhou, Z.; Wu, X.; Liang, H. Comparison of binding characterization of two antiviral drugs to human serum albumin. Chem. Biol. Drug Des., 2014, 83(5), 576-582.
[http://dx.doi.org/10.1111/cbdd.12270] [PMID: 24325603]
(c)Petitpas, I.; Petersen, C.E.; Ha, C.E.; Bhattacharya, A.A.; Zunszain, P.A.; Ghuman, J.; Bhagavan, N.V.; Curry, S. Structural basis of albumin-thyroxine interactions and familial dysalbuminemic hyperthyroxinemia. Proc. Natl. Acad. Sci. USA, 2003, 100(11), 6440-6445.
[http://dx.doi.org/10.1073/pnas.1137188100] [PMID: 12743361]
(d)Yang, F.; Yue, J.; Ma, L.; Ma, Z.; Li, M.; Wu, X.; Liang, H. Interactive associations of drug-drug and drug-drug-drug with IIA subdomain of human serum albumin. Mol. Pharm., 2012, 9(11), 3259-3265.
[http://dx.doi.org/10.1021/mp300322y] [PMID: 23009653]

Yang, F.; Liang, H. Editorial: HSA-based drug development and drug delivery systems. Curr. Pharm. Des., 2015, 21(14), 1784-1784.
[http://dx.doi.org/10.2174/138161282114150326101436] [PMID: 25837717]

(a)Banerjee, A.; Basu, K.; Sengupta, P.K. Interaction of 7-hydroxyflavone with human serum albumin: A spectroscopic study. J. Photochem. Photobiol. B, 2008, 90(1), 33-40.
[http://dx.doi.org/10.1016/j.jphotobiol.2007.10.005] [PMID: 18068375]
(b)Bos, O.J.; Fischer, M.J.; Wilting, J.; Janssen, L.H. Drug-binding and other physicochemical properties of a large tryptic and a large peptic fragment of human serum albumin. Biochim. Biophys. Acta, 1988, 953(1), 37-47.
[http://dx.doi.org/10.1016/0167-4838(88)90007-6] [PMID: 3124878]
(c)Boulton, D.W.; Walle, U.K.; Walle, T. Extensive binding of the bioflavonoid quercetin to human plasma proteins. J. Pharm. Pharmacol., 1998, 50(2), 243-249.
[http://dx.doi.org/10.1111/j.2042-7158.1998.tb06183.x] [PMID: 9530994]
(d)Dangles, O.; Dufour, C.; Manach, C.; Morand, C.; Remesy, C. Binding of flavonoids to plasma proteins. Methods Enzymol., 2001, 335, 319-333.
[http://dx.doi.org/10.1016/S0076-6879(01)35254-0] [PMID: 11400381]
(e)Manach, C.; Morand, C.; Texier, O.; Favier, M.L.; Agullo, G.; Demigné, C.; Régérat, F.; Rémésy, C. Quercetin metabolites in plasma of rats fed diets containing rutin or quercetin. J. Nutr., 1995, 125(7), 1911-1922.
[http://dx.doi.org/10.1093/jn/125.7.1911] [PMID: 7616308]
(f)Mandeville, J.S.; Froehlich, E.; Tajmir-Riahi, H.A. Study of curcumin and genistein interactions with human serum albumin. J. Pharm. Biomed. Anal., 2009, 49(2), 468-474.
[http://dx.doi.org/10.1016/j.jpba.2008.11.035] [PMID: 19135819]
(g)Patra, D. Synchronous fluorescence based biosensor for albumin determination by cooperative binding of fluorescence probe in a supra-biomolecular host-protein assembly. Biosens. Bioelectron., 2010, 25(5), 1149-1154.
[http://dx.doi.org/10.1016/j.bios.2009.09.041] [PMID: 19880306]
(h)Patra, D.; Ghaddar, T.H. Application of synchronous fluorescence scan spectroscopy for size dependent simultaneous analysis of CdTe nanocrystals and their mixtures. Talanta, 2009, 77(4), 1549-1554.
[http://dx.doi.org/10.1016/j.talanta.2008.09.007] [PMID: 19084678]
(i)Pulla Reddy, A.C.; Sudharshan, E.; Appu Rao, A.G.; Lokesh, B.R. Interaction of curcumin with human serum albumin-a spectroscopic study. Lipids, 1999, 34(10), 1025-1029.
[http://dx.doi.org/10.1007/s11745-999-0453-x] [PMID: 10580329]
(j)Sengupta, B.; Sengupta, P.K. The interaction of quercetin with human serum albumin: A fluorescence spectroscopic study. Biochem. Biophys. Res. Commun., 2002, 299(3), 400-403.
[http://dx.doi.org/10.1016/S0006-291X(02)02667-0] [PMID: 12445814]
(k)Sengupta, B.; Sengupta, P.K. Binding of quercetin with human serum albumin: A critical spectroscopic study. Biopolymers, 2003, 72(6), 427-434.
[http://dx.doi.org/10.1002/bip.10489] [PMID: 14587065]
(l)Sochacka, J.; Baran, W. The investigation of the binding of 6-mercaptopurine to site I on human serum albumin. Protein J., 2012, 31(8), 689-702.
[http://dx.doi.org/10.1007/s10930-012-9449-y] [PMID: 23001616]
(m)Tang, J.; Luan, F.; Chen, X. Binding analysis of glycyrrhetinic acid to human serum albumin: Fluorescence spectroscopy, FTIR, and molecular modeling. Bioorg. Med. Chem., 2006, 14(9), 3210-3217.
[http://dx.doi.org/10.1016/j.bmc.2005.12.034] [PMID: 16412649]
(n)Yue, Y.; Chen, X.; Qin, J.; Yao, X. Characterization of the mangiferin-human serum albumin complex by spectroscopic and molecular modeling approaches. J. Pharm. Biomed. Anal., 2009, 49(3), 753-759.
[http://dx.doi.org/10.1016/j.jpba.2008.12.017] [PMID: 19157745]
(o)Zsila, F.; Bikádi, Z.; Simonyi, M. Probing the binding of the flavonoid, quercetin to human serum albumin by circular dichroism, electronic absorption spectroscopy and molecular modelling methods. Biochem. Pharmacol., 2003, 65(3), 447-456.
[http://dx.doi.org/10.1016/S0006-2952(02)01521-6] [PMID: 12527338]

Tanzadehpanah, H.; Mahaki, H.; Moradi, M.; Afshar, S.; Moghadam, N.H.; Salehzadeh, S.; Najafi, R.; Amini, R.; Saidijam, M. The use of molecular docking and spectroscopic methods for investigation of the interaction between regorafenib with human serum albumin (HSA) and calf thymus DNA (Ct-DNA) in the presence of different site markers. Protein Pept. Lett., 2021, 28(3), 290-303.
[http://dx.doi.org/10.2174/0929866527666200921164536] [PMID: 32957871]

(a)Levy, O.; Brennen, W.N.; Han, E.; Rosen, D.M.; Musabeyezu, J.; Safaee, H.; Ranganath, S.; Ngai, J.; Heinelt, M.; Milton, Y.; Wang, H.; Bhagchandani, S.H.; Joshi, N.; Bhowmick, N.; Denmeade, S.R.; Isaacs, J.T.; Karp, J.M. A prodrug-doped cellular trojan horse for the potential treatment of prostate cancer. Biomaterials, 2016, 91, 140-150.
[http://dx.doi.org/10.1016/j.biomaterials.2016.03.023] [PMID: 27019026]
(b)Rossi, A.; Di Maio, M. Platinum-based chemotherapy in advanced non-small-cell lung cancer: Optimal number of treatment cycles. Expert Rev. Anticancer Ther., 2016, 16(6), 653-660.
[http://dx.doi.org/10.1586/14737140.2016.1170596] [PMID: 27010977]
(c)Wong, K.E.; Mora, M.C.; Skinner, M.; McRae Page, S.; Crisi, G.M.; Arenas, R.B.; Schneider, S.S.; Emrick, T. Evaluation of PolyMPC-Dox prodrugs in a human ovarian tumor model. Mol. Pharm., 2016, 13(5), 1679-1687.
[http://dx.doi.org/10.1021/acs.molpharmaceut.6b00092] [PMID: 27023764]
(d)Xie, H.; Xu, X.; Chen, J.; Li, L.; Wang, J.; Fang, T.; Zhou, L.; Wang, H.; Zheng, S. Rational design of multifunctional small-molecule prodrugs for simultaneous suppression of cancer cell growth and metastasis in vitro and in vivo. Chem. Commun. (Camb.), 2016, 52(32), 5601-5604.
[http://dx.doi.org/10.1039/C5CC10367C] [PMID: 27027105]
(e)Mikhaylenko, D.S.; Efremov, G.D.; Sivkov, A.V.; Zaletaev, D.V. Hormone resistance and neuroendocrine differentiation due to accumulation of genetic lesions during clonal evolution of prostate cancer. Mol. Biol. (Mosk.), 2016, 50(1), 34-43.
[PMID: 27028809]
(f)Moehler, M.; Delic, M.; Goepfert, K.; Aust, D.; Grabsch, H.I.; Halama, N.; Heinrich, B.; Julie, C.; Lordick, F.; Lutz, M.P.; Mauer, M.; Alsina Maqueda, M.; Schild, H.; Schimanski, C.C.; Wagner, A.D.; Roth, A.; Ducreux, M. Immunotherapy in gastrointestinal cancer: Recent results, current studies and future perspectives. Eur. J. Cancer, 2016, 59, 160-170.
[http://dx.doi.org/10.1016/j.ejca.2016.02.020] [PMID: 27039171]

(a)Dandawate, P.R.; Vyas, A.; Ahmad, A.; Banerjee, S.; Deshpande, J.; Swamy, K.V.; Jamadar, A.; Dumhe-Klaire, A.C.; Padhye, S.; Sarkar, F.H. Inclusion complex of novel curcumin analogue CDF and β-cyclodextrin (1:2) and its enhanced in vivo anticancer activity against pancreatic cancer. Pharm. Res., 2012, 29(7), 1775-1786.
[http://dx.doi.org/10.1007/s11095-012-0700-1] [PMID: 22322899]
(b)Ghatak, S.; Vyas, A.; Misra, S.; O’Brien, P.; Zambre, A.; Fresco, V.M.; Markwald, R.R.; Swamy, K.V.; Afrasiabi, Z.; Choudhury, A.; Khetmalas, M.; Padhye, S. Novel di-tertiary-butyl phenylhydrazones as dual cyclooxygenase-2/5-lipoxygenase inhibitors: Synthesis, COX/LOX inhibition, molecular modeling, and insights into their cytotoxicities. Bioorg. Med. Chem. Lett., 2014, 24(1), 317-324.
[http://dx.doi.org/10.1016/j.bmcl.2013.11.015] [PMID: 24295787]
(c)Kanwar, S.S.; Yu, Y.; Nautiyal, J.; Patel, B.B.; Padhye, S.; Sarkar, F.H.; Majumdar, A.P. Difluorinated-curcumin (CDF): A novel curcumin analog is a potent inhibitor of colon cancer stem-like cells. Pharm. Res., 2011, 28(4), 827-838.
[http://dx.doi.org/10.1007/s11095-010-0336-y] [PMID: 21161336]
(d)Misra, S.; Ghatak, S.; Vyas, A.; O’Brien, P.; Markwald, R.R.; Khetmalas, M.; Hascall, V.C.; McCarthy, J.B.; Karamanos, N.K.; Tammi, M.I.; Tammi, R.H.; Prestwitch, G.D.; Padhye, S. Isothiocyanate analogs targeting CD44 receptor as an effective strategy against colon cancer. Med. Chem. Res., 2014, 23(8), 3836-3851.
[http://dx.doi.org/10.1007/s00044-014-0958-4] [PMID: 25013352]
(e)Roy, S.; Yu, Y.; Padhye, S.B.; Sarkar, F.H.; Majumdar, A.P. Difluorinated-curcumin (CDF) restores PTEN expression in colon cancer cells by down-regulating miR-21. PLoS One, 2013, 8(7), e68543.
[http://dx.doi.org/10.1371/journal.pone.0068543] [PMID: 23894315]
(f)Sahin, K.; Orhan, C.; Tuzcu, M.; Muqbil, I.; Sahin, N.; Gencoglu, H.; Guler, O.; Padhye, S.B.; Sarkar, F.H.; Mohammad, R.M. Comparative in vivo evaluations of curcumin and its analog difluorinated curcumin against cisplatin-induced nephrotoxicity. Biol. Trace Elem. Res., 2014, 157(2), 156-163.
[http://dx.doi.org/10.1007/s12011-014-9886-x] [PMID: 24415068]
(g)Salvioli, S.; Sikora, E.; Cooper, E.L.; Franceschi, C. Curcumin in cell death processes: A challenge for CAM of age-related pathologies. Evid. Based Complement. Alternat. Med., 2007, 4(2), 181-190.
[http://dx.doi.org/10.1093/ecam/nem043] [PMID: 17549234]
(h)Saquib, Q.; Al-Khedhairy, A.A.; Alarifi, S.A.; Dwivedi, S.; Mustafa, J.; Musarrat, J. Fungicide methyl thiophanate binding at sub-domain IIA of human serum albumin triggers conformational change and protein damage. Int. J. Biol. Macromol., 2010, 47(1), 60-67.
[http://dx.doi.org/10.1016/j.ijbiomac.2010.03.020] [PMID: 20371370]
(i)Williams, R.J.; Spencer, J.P.; Rice-Evans, C. Flavonoids: Antioxidants or signalling molecules? Free Radic. Biol. Med., 2004, 36(7), 838-849.
[http://dx.doi.org/10.1016/j.freeradbiomed.2004.01.001] [PMID: 15019969]

(a)Kesharwani, P.; Banerjee, S.; Padhye, S.; Sarkar, F.H.; Iyer, A.K. Hyaluronic acid engineered nanomicelles loaded with 3,4-Difluorobenzylidene curcumin for targeted killing of CD44+ stem-like pancreatic cancer cells. Biomacromolecules, 2015, 16(9), 3042-3053.
[http://dx.doi.org/10.1021/acs.biomac.5b00941] [PMID: 26302089]
(b)Kesharwani, P.; Banerjee, S.; Padhye, S.; Sarkar, F.H.; Iyer, A.K. Parenterally administrable nano-micelles of 3,4-difluorobenzylidene curcumin for treating pancreatic cancer. Colloids Surf. B Biointerfaces, 2015, 132, 138-145.
[http://dx.doi.org/10.1016/j.colsurfb.2015.05.007] [PMID: 26037703]
(c)Kesharwani, P.; Xie, L.; Banerjee, S.; Mao, G.; Padhye, S.; Sarkar, F.H.; Iyer, A.K. Hyaluronic acid-conjugated polyamidoamine dendrimers for targeted delivery of 3,4-difluorobenzylidene curcumin to CD44 overexpressing pancreatic cancer cells. Colloids Surf. B Biointerfaces, 2015, 136, 413-423.
[http://dx.doi.org/10.1016/j.colsurfb.2015.09.043] [PMID: 26440757]

(a)Carter, D.C.; Chang, B.; Ho, J.X.; Keeling, K.; Krishnasami, Z. Preliminary crystallographic studies of four crystal forms of serum albumin. Eur. J. Biochem., 1994, 226(3), 1049-1052.
[http://dx.doi.org/10.1111/j.1432-1033.1994.01049.x] [PMID: 7813459]
(b)Carter, D.C.; He, X.M.; Munson, S.H.; Twigg, P.D.; Gernert, K.M.; Broom, M.B.; Miller, T.Y. Three-dimensional structure of human serum albumin. Science, 1989, 244(4909), 1195-1198.
[http://dx.doi.org/10.1126/science.2727704] [PMID: 2727704]

Curry, S.; Mandelkow, H.; Brick, P.; Franks, N. Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites. Nat. Struct. Biol., 1998, 5(9), 827-835.
[http://dx.doi.org/10.1038/1869] [PMID: 9731778]

Sugio, S.; Kashima, A.; Mochizuki, S.; Noda, M.; Kobayashi, K. Crystal structure of human serum albumin at 2.5 A resolution. Protein Eng., 1999, 12(6), 439-446.
[http://dx.doi.org/10.1093/protein/12.6.439] [PMID: 10388840]

(a)Sudlow, G.; Birkett, D.J.; Wade, D.N. The characterization of two specific drug binding sites on human serum albumin. Mol. Pharmacol., 1975, 11(6), 824-832.
[PMID: 1207674]
(b)Sudlow, G.; Birkett, D.J.; Wade, D.N. Further characterization of specific drug binding sites on human serum albumin. Mol. Pharmacol., 1976, 12(6), 1052-1061.
[PMID: 1004490]

Bos, O.J.; Remijn, J.P.; Fischer, M.J.; Wilting, J.; Janssen, L.H. Location and characterization of the warfarin binding site of human serum albumin. A comparative study of two large fragments. Biochem. Pharmacol., 1988, 37(20), 3905-3909.
[http://dx.doi.org/10.1016/0006-2952(88)90072-X] [PMID: 3190737]

Simard, J.R.; Zunszain, P.A.; Hamilton, J.A.; Curry, S. Location of high and low affinity fatty acid binding sites on human serum albumin revealed by NMR drug-competition analysis. J. Mol. Biol., 2006, 361(2), 336-351.
[http://dx.doi.org/10.1016/j.jmb.2006.06.028] [PMID: 16844140]

Elion, G.B. The purine path to chemotherapy. Science, 1989, 244(4900), 41-47.
[http://dx.doi.org/10.1126/science.2649979] [PMID: 2649979]

(a)Dean, B.M.; Perrett, D.; Simmonds, H.A.; Grahame, R. Thiopurinol: Comparative enzyme inhibition and protein binding studies with allopurinol, oxipurinol and 6-mercaptopurine. Br. J. Clin. Pharmacol., 1974, 1(2), 119-127.
[http://dx.doi.org/10.1111/j.1365-2125.1974.tb00220.x] [PMID: 22454898]
(b)Sjöholm, I.; Stjerna, B. Binding of drugs to human serum albumin XVII: Irreversible binding of mercaptopurine to human serum proteins. J. Pharm. Sci., 1981, 70(11), 1290-1291.
[http://dx.doi.org/10.1002/jps.2600701130] [PMID: 7197718]

(a)Jeelani, I.; Itaya, K.; Abe, H. Total synthesis of hyalodendriol C. Heterocycles, 2021, 102(8), 1570-1578.
(b)Hu, Y.J.; Liu, Y.; Xiao, X.H. Investigation of the interaction between berberine and human serum albumin. Biomacromolecules, 2009, 10(3), 517-521.
[http://dx.doi.org/10.1021/bm801120k] [PMID: 19173654]

Patra, D. Simple luminescence method for estimation of benzo[a]pyrene in a complex mixture of polycyclic aromatic hydrocarbons without a pre-separation procedure. Luminescence, 2003, 18(2), 97-102.
[http://dx.doi.org/10.1002/bio.712] [PMID: 12687629]

Matsukawa, Y.; Marui, N.; Sakai, T.; Satomi, Y.; Yoshida, M.; Matsumoto, K.; Nishino, H.; Aoike, A. Genistein arrests cell cycle progression at G2-M. Cancer Res., 1993, 53(6), 1328-1331.
[PMID: 8443813]

Itaya, K.; Jeelani, I.; Abe, H. Total synthesis of urolithin C 3-glucuronide (dedicated to professor Dr. Yasuyuki Kita on the occasion of his 77th birthday). Heterocycles, 2021, 103(2), 1038-1047.

Wang, Y.Q.; Zhang, H.M.; Zhang, G.C. Studies of the interaction between palmatine hydrochloride and human serum albumin by fluorescence quenching method. J. Pharm. Biomed. Anal., 2006, 41(3), 1041-1046.
[http://dx.doi.org/10.1016/j.jpba.2006.01.028] [PMID: 16549318]

Abe, H.; Jeelani, I.; Yonoki, A.; Imai, H.; Horino, Y. Synthesis of chloro-substituted 6H-dibenzo[b,d]pyran-6-one natural products, graphislactone G, and palmariols A and B. Chem. Pharm. Bull. (Tokyo), 2021, 69(8), 781-788.
[http://dx.doi.org/10.1248/cpb.c21-00316] [PMID: 34334522]

Hagemeister, F.; Cabanillas, F.; Coleman, M.; Gregory, S.A.; Zinzani, P.L. The role of mitoxantrone in the treatment of indolent lymphomas. Oncologist, 2005, 10(2), 150-159.
[http://dx.doi.org/10.1634/theoncologist.10-2-150] [PMID: 15709217]

(a)Ishtikhar, M.; Rabbani, G.; Khan, S.; Khan, R.H. Biophysical investigation of thymoquinone binding to ‘N’ and ‘B’ isoforms of human serum albumin: Exploring the interaction mechanism and radical scavenging activity. RSC Advances, 2015, 5(24), 18218-18232.
[http://dx.doi.org/10.1039/C4RA09892G]
(b)Lupidi, G.; Scire, A.; Camaioni, E.; Khalife, K.H.; De Sanctis, G.; Tanfani, F.; Damiani, E. Thymoquinone, a potential therapeutic agent of Nigella sativa, binds to site I of human serum albumin. Phytomedicine, 2010, 17(10), 714-720.
[http://dx.doi.org/10.1016/j.phymed.2010.01.011] [PMID: 20171066]
(c)Yasseen, Z.J.; Hammad, J.H. ALTalla, H.A. Thermodynamic analysis of thymoquinone binding to human serum albumin. Spectrochim. Acta A Mol. Biomol. Spectrosc., 2014, 124, 677-681.
[http://dx.doi.org/10.1016/j.saa.2013.12.112] [PMID: 24582953]

Wu, N.; Kong, Y.; Zu, Y.; Fu, Y.; Liu, Z.; Meng, R.; Liu, X.; Efferth, T. Activity investigation of pinostrobin towards herpes simplex virus-1 as determined by atomic force microscopy. Phytomedicine, 2011, 18(2-3), 110-118.
[http://dx.doi.org/10.1016/j.phymed.2010.07.001] [PMID: 20739162]

Feroz, S.R.; Mohamad, S.B.; Bakri, Z.S.; Malek, S.N.; Tayyab, S. Probing the interaction of a therapeutic flavonoid, pinostrobin with human serum albumin: Multiple spectroscopic and molecular modeling investigations. PLoS One, 2013, 8(10), e76067.
[http://dx.doi.org/10.1371/journal.pone.0076067] [PMID: 24116089]

Walle, T. Absorption and metabolism of flavonoids. Free Radic. Biol. Med., 2004, 36(7), 829-837.
[http://dx.doi.org/10.1016/j.freeradbiomed.2004.01.002] [PMID: 15019968]

Guharay, J.; Sengupta, B.; Sengupta, P.K. Protein-flavonol interaction: Fluorescence spectroscopic study. Proteins, 2001, 43(2), 75-81.
[http://dx.doi.org/10.1002/1097-0134(20010501)43:2<75::AID-PROT1019>3.0.CO;2-7] [PMID: 11276077]

Sytnik, A.; Litvinyuk, I. Energy transfer to a proton-transfer fluorescence probe: Tryptophan to a flavonol in human serum albumin. Proc. Natl. Acad. Sci. USA, 1996, 93(23), 12959-12963.
[http://dx.doi.org/10.1073/pnas.93.23.12959] [PMID: 8917526]

(a)Kandil, S.; Westwell, A.D.; McGuigan, C. 7-Substituted umbelliferone derivatives as androgen receptor antagonists for the potential treatment of prostate and breast cancer. Bioorg. Med. Chem. Lett., 2016, 26(8), 2000-2004.
[http://dx.doi.org/10.1016/j.bmcl.2016.02.088] [PMID: 26965862]
(b)Salem, M.A.; Marzouk, M.I.; El-Kazak, A.M. Synthesis and characterization of some new coumarins with in vitro antitumor and antioxidant activity and high protective effects against DNA damage. Molecules, 2016, 21(2), 249.
[http://dx.doi.org/10.3390/molecules21020249] [PMID: 26907244]
(c)VenkataSairam, K.; Gurupadayya, B.M.; Chandan, R.S.; Nagesha, D.K.; Vishwanathan, B. A review on chemical profile of coumarins and their therapeutic role in the treatment of cancer. Curr. Drug Deliv., 2016, 13(2), 186-201.
[PMID: 26135671]
(d)Wen, Y.C.; Lee, W.J.; Tan, P.; Yang, S.F.; Hsiao, M.; Lee, L.M.; Chien, M.H. By inhibiting snail signaling and miR-23a-3p, osthole suppresses the EMT-mediated metastatic ability in prostate cancer. Oncotarget, 2015, 6(25), 21120-21136.
[http://dx.doi.org/10.18632/oncotarget.4229] [PMID: 26110567]

(a)Ren, C.M.; Li, Y.; Chen, Q.Z.; Zeng, Y.H.; Shao, Y.; Wu, Q.X.; Yuan, S.X.; Yang, J.Q.; Yu, Y.; Wu, K.; He, B.C.; Sun, W.J. Oridonin inhibits the proliferation of human colon cancer cells by upregulating BMP7 to activate p38 MAPK. Oncol. Rep., 2016, 35(5), 2691-2698.
[http://dx.doi.org/10.3892/or.2016.4654] [PMID: 26986967]
(b)Shi, M.; Lu, X.J.; Zhang, J.; Diao, H.; Li, G.; Xu, L.; Wang, T.; Wei, J.; Meng, W.; Ma, J.L.; Yu, H.; Wang, Y.G. Oridonin, a novel lysine acetyltransferases inhibitor, inhibits proliferation and induces apoptosis in gastric cancer cells through p53- and caspase-3-mediated mechanisms. Oncotarget, 2016, 7(16), 22623-22631.
[http://dx.doi.org/10.18632/oncotarget.8033] [PMID: 26980707]
(c)Xia, R.; Chen, S.X.; Qin, Q.; Chen, Y.; Zhang, W.W.; Zhu, R.R.; Deng, A.M. Oridonin suppresses proliferation of human ovarian cancer cells via blockage of mTOR signaling. Asian Pac. J. Cancer Prev., 2016, 17(2), 667-671.
[http://dx.doi.org/10.7314/APJCP.2016.17.2.667] [PMID: 26925661]

(a)Ding, Q.; Li, H.; Tian, X.; Shen, Z.; Wang, X.; Mo, F.; Huang, J.; Shen, H. Zinc and imipramine reverse the depression-like behavior in mice induced by chronic restraint stress. J. Affect. Disord., 2016, 197, 100-106.
[http://dx.doi.org/10.1016/j.jad.2016.03.017] [PMID: 26985741]
(b)Duda, W.; Curzytek, K.; Kubera, M.; Iciek, M.; Kowalczyk-Pachel, D.; Bilska-Wilkosz, A.; Lorenc-Koci, E.; Leśkiewicz, M.; Basta-Kaim, A.; Budziszewska, B.; Regulska, M.; Ślusarczyk, J.; Gruca, P.; Papp, M.; Maes, M.; Lasoń, W.; Antkiewicz-Michaluk, L. The effect of chronic mild stress and imipramine on the markers of oxidative stress and antioxidant system in rat liver. Neurotox. Res., 2016, 30(2), 173-184.
[http://dx.doi.org/10.1007/s12640-016-9614-8] [PMID: 26961706]

Rajamanickam, S.; Panneerdoss, S.; Gorthi, A.; Timilsina, S.; Onyeagucha, B.; Kovalskyy, D.; Ivanov, D.; Hanes, M.A.; Vadlamudi, R.K.; Chen, Y.; Bishop, A.J.; Arbiser, J.L.; Rao, M.K. Inhibition of FoxM1-mediated DNA repair by imipramine blue suppresses breast cancer growth and metastasis. Clin. Cancer Res., 2016, 22(14), 3524-3536.
[http://dx.doi.org/10.1158/1078-0432.CCR-15-2535] [PMID: 26927663]

Yoo, M.J.; Smith, Q.R.; Hage, D.S. Studies of imipramine binding to human serum albumin by high-performance affinity chromatography. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2009, 877(11-12), 1149-1154.
[http://dx.doi.org/10.1016/j.jchromb.2009.02.070] [PMID: 19328747]

Das Gupta, S.; Suh, N. Tocopherols in cancer: An update. Mol. Nutr. Food Res., 2016, 60(6), 1354-1363.
[http://dx.doi.org/10.1002/mnfr.201500847] [PMID: 26751721]

(a)Li, X.; Chen, D.; Wang, G.; Lu, Y. Study of interaction between human serum albumin and three antioxidants: Ascorbic acid, α-tocopherol, and proanthocyanidins. Eur. J. Med. Chem., 2013, 70, 22-36.
[http://dx.doi.org/10.1016/j.ejmech.2013.09.033] [PMID: 24140914]
(b)Fanali, G.; Fasano, M.; Ascenzi, P.; Zingg, J.M.; Azzi, A. α-tocopherol binding to human serum albumin. Biofactors, 2013, 39(3), 294-303.
[http://dx.doi.org/10.1002/biof.1070] [PMID: 23355326]

(a)Resende, F.A.; de Oliveira, A.P.; de Camargo, M.S.; Vilegas, W.; Varanda, E.A. Evaluation of estrogenic potential of flavonoids using a recombinant yeast strain and MCF7/BUS cell proliferation assay. PLoS One, 2013, 8(10), e74881.
[http://dx.doi.org/10.1371/journal.pone.0074881] [PMID: 24098354]
(b)Zemanova, L.; Hofman, J.; Novotna, E.; Musilek, K.; Lundova, T.; Havrankova, J.; Hostalkova, A.; Chlebek, J.; Cahlikova, L.; Wsol, V. Flavones inhibit the activity of AKR1B10, a promising therapeutic target for cancer treatment. J. Nat. Prod., 2015, 78(11), 2666-2674.
[http://dx.doi.org/10.1021/acs.jnatprod.5b00616] [PMID: 26529431]
(c)Zhang, T.; Du, J.; Liu, L.; Chen, X.; Yang, F.; Jin, Q. Inhibitory effects and underlying mechanism of 7-hydroxyflavone phosphate ester in HeLa cells. PLoS One, 2012, 7(5), e36652.
[http://dx.doi.org/10.1371/journal.pone.0036652] [PMID: 22574207]

Qi, Z.D.; Zhang, Y.; Liao, F.L.; Ou-Yang, Y.W.; Liu, Y.; Yang, X. Probing the binding of morin to human serum albumin by optical spectroscopy. J. Pharm. Biomed. Anal., 2008, 46(4), 699-706.
[http://dx.doi.org/10.1016/j.jpba.2007.10.016] [PMID: 18178358]

Bahram Hemmateenejad, M.S.; Samari, F.; Khayamian, T.; Ebrahimi, M.; Rezaei, Z. Combined fluorescence spectroscopy and molecular modelling studies on the interaction between harmalol and human serum albumin. J. Pharm. Biomed. Anal., 2012, 67-68, 201-208.
[PMID: 22560122]